Related Experiment Videos
[Detection of minimal residual disease using reverse transcriptase polymerase chain reaction technique]
Nihon Rinsho. Japanese Journal of Clinical Medicine
|June 1, 1992
Summary
Reverse transcriptase PCR (RT-PCR) detects minimal residual disease (MRD) in acute lymphoblastic leukemia. This sensitive method aids in assessing remission depth, predicting relapse, and evaluating cancer treatment effectiveness.
Area of Science:
- Molecular biology
- Oncology
- Hematology
Context:
- Hematological malignancies like acute lymphoblastic leukemia (ALL) require sensitive methods for detecting minimal residual disease (MRD).
- Standard PCR may be limited when tumor-specific breakpoints are large, necessitating alternative amplification strategies.
- Reverse transcriptase PCR (RT-PCR) offers a solution by amplifying chimeric messenger RNA (mRNA) derived from specific genomic rearrangements.
Purpose:
- To apply RT-PCR for the sensitive detection of MRD in patients diagnosed with t(1;19) acute lymphoblastic leukemia.
- To evaluate the utility of RT-PCR as a tool for monitoring leukemia patients.
Summary:
- This study utilized reverse transcriptase PCR (RT-PCR) to detect minimal residual disease (MRD) in patients with t(1;19) acute lymphoblastic leukemia (ALL).
- RT-PCR amplifies chimeric mRNA, enabling sensitive detection of leukemia-specific sequences even with large genomic DNA breakpoints.
- The method proved effective for identifying residual cancer cells post-treatment.
Impact:
- RT-PCR can enhance the assessment of remission depth in leukemia patients.
- This technique may allow for the early detection of preclinical relapse, enabling timely intervention.
- RT-PCR is valuable for evaluating the efficacy of ex vivo purging strategies in autologous bone marrow transplantation for leukemia.